Sign in
CompletedPhase 1/2

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

Key facts

Who runs it
Pfizer
Where
Anaheim, Brownsville, Charlottesville, Chesterfield, Durham, Hialeah, Hollywood, Honolulu, Kansas City, Lake Forest, Mesquite, Miami Lakes, Milford, Mobile, New Orleans, Norfolk, Orlando, Philadelphia, Raleigh, Rochester, Saint Paul, Salt Lake City, San Antonio, San Diego, Scottsdale, South Miami, Tomball, and Walnut Creek, United StatesSee the 32 sites
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
1,202 people enrolled
Started
23 May 2024
Ended
5 Feb 2025
Type of study
Interventional, 19 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Influenza ModRNA Vaccine
  • Quadrivalent Influenza Vaccine (QIV)
Record updated
12 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Applies to all 3 substudies:
  • participants ≥18 years of age
  • generally healthy participants; Substudy C ONLY:
  • receipt of licensed influenza vaccination for the 2023-2024 flu season at least 6 months ago

Who cannot take part

  • receipt of any investigational or licensed influenza vaccines within 6 months
  • All 3 substudies:
  • diagnosis of influenza (by clinical testing) in the last 6 months
  • immunocompromised individuals with known or suspected immunodeficiency

Where in United States

  • Anaheim Clinical Trials, LLCAnaheim, United States
  • Headlands Horizons LLCBrownsville, United States
  • Charlottesville Medical ResearchCharlottesville, United States
  • Clinical Research ProfessionalsChesterfield, United States
  • Duke Vaccine and Trials UnitDurham, United States
  • Indago Research & Health Center, IncHialeah, United States
  • Research Centers of AmericaHollywood, United States
  • Research Centers of America (Hollywood)Hollywood, United States
  • East-West Medical Research InstituteHonolulu, United States
  • Alliance for Multispecialty Research, LLCKansas City, United States
  • Orange County Research CenterLake Forest, United States
  • SMS Clinical ResearchMesquite, United States
  • Palm Springs Community Health CenterMiami Lakes, United States
  • Clinical Research ConsultingMilford, United States
  • AMR ClinicalMobile, United States
  • Alliance for Multispecialty Research, LLCNew Orleans, United States
  • AMR ClinicalNorfolk, United States
  • Clinical Neuroscience Solutions, Inc.Orlando, United States
  • Headlands Research OrlandoOrlando, United States
  • DM Clinical Research - PhiladelphiaPhiladelphia, United States
  • M3 Wake Research, Inc.Raleigh, United States
  • Rochester Clinical Research, LLCRochester, United States
  • Prism Research LLC dba Nucleus NetworkSaint Paul, United States
  • J. Lewis Research, Inc. / Foothill Family ClinicSalt Lake City, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic SouthSalt Lake City, United States
  • Clinical Trials of Texas LLCSan Antonio, United States
  • Clinical Trials of Texas, LLC., dba Flourish ResearchSan Antonio, United States
  • Artemis Institute for Clinical ResearchSan Diego, United States
  • Headlands Research - ScottsdaleScottsdale, United States
  • Qps-Mra, LlcSouth Miami, United States
  • Dynamed Clinical Research, LP d/b/a DM Clinical ResearchTomball, United States
  • Diablo Clinical Research, Inc.Walnut Creek, United States

About the trial

What the trial wants to find out

The purpose of this study is to learn if modified RNA (modRNA) vaccines for the prevention of influenza are:

Read full original descriptionShow less

* safe; and * how these vaccines produce an immune response in generally healthy adults. Immune response is the way the body protects itself against things it sees as harmful or foreign.

RNA (also called ribonucleic acid) is one of two types of nucleic acid made by cells. RNA contains information that has been copied from DNA (the other type of nucleic acid). Cells make several different forms of RNA, and each form has a specific job in the cell. Many forms of RNA have functions related to making proteins. RNA is also the genetic material of some viruses instead of DNA. RNA can be made in the laboratory and used in research studies. Also called ribonucleic acid.

Influenza is term used for flu illness. It is an infection caused by a virus that affects your mouth, nose, and throat.

The study is seeking for participants who:

* are at least 18 years of age * have not received an influenza vaccine within the last 6 months * are generally healthy

This study will be divided into three sub-studies: Substudy A (SSA), Substudy B (SSB), and Substudy C (SSC).

All participants, regardless of sub-study, will receive 1 dose of either of the following vaccines as an injection into their arm:

* 1 of the modRNA influenza vaccines that is being studied; or * an approved influenza vaccine approved for use in their respective age group.

Participants will be involved in this study for about 6 months. During this time, participants will have at least 3 clinic visits.

The 19 groups in the trial

  • SSA: Influenza ModRNA Vaccine 2ATreatment being tested

    \- Single Dose on Day 1

    Treatment: Influenza ModRNA Vaccine

  • SSA: Influenza ModRNA Vaccine 3ATreatment being tested

    \- Single Dose on Day 1

    Treatment: Influenza ModRNA Vaccine

  • SSA: Influenza ModRNA Vaccine 4ATreatment being tested

    \- Single Dose on Day 1

    Treatment: Influenza ModRNA Vaccine

  • SSA: Influenza ModRNA Vaccine 5ATreatment being tested

    \- Single dose on Day 1

    Treatment: Influenza ModRNA Vaccine

  • SSA: QIV1Existing treatment, for comparison

    \- Single dose on Day 1

    Treatment: Quadrivalent Influenza Vaccine (QIV)

  • SSB: Influenza ModRNA Vaccine 3BTreatment being tested

    \- Single Dose on Day 1

    Treatment: Influenza ModRNA Vaccine

  • SSB: Influenza ModRNA Vaccine 4BTreatment being tested

    \- Single Dose on Day 1

    Treatment: Influenza ModRNA Vaccine

  • SSB: Influenza ModRNA Vaccine 5BTreatment being tested

    \- Single dose on Day 1

    Treatment: Influenza ModRNA Vaccine

  • SSB: QIV2Existing treatment, for comparison

    \- Single Dose on Day 1

    Treatment: Quadrivalent Influenza Vaccine (QIV)

  • SSB: QIV3Existing treatment, for comparison

    \- Single Dose on Day 1

    Treatment: Quadrivalent Influenza Vaccine (QIV)

  • SSC: Influenza ModRNA Vaccine 3CTreatment being tested

    \- Single Dose on Day 1

    Treatment: Influenza ModRNA Vaccine

  • SSC: Influenza ModRNA Vaccine 4CTreatment being tested

    \- Single Dose on Day 1

    Treatment: Influenza ModRNA Vaccine

  • SSC: Influenza ModRNA Vaccine 5CTreatment being tested

    \- Single Dose on Day 1

    Treatment: Influenza ModRNA Vaccine

  • SSC: Influenza ModRNA Vaccine 6CTreatment being tested

    \- Single Dose on Day 1

    Treatment: Influenza ModRNA Vaccine

  • SSC: Influenza ModRNA Vaccine 7CTreatment being tested

    \- Single Dose on Day 1

    Treatment: Influenza ModRNA Vaccine

  • SSC: Influenza ModRNA Vaccine 8CTreatment being tested

    \- Single Dose on Day 1

    Treatment: Influenza ModRNA Vaccine

  • SSC: Influenza ModRNA Vaccine 9CTreatment being tested

    \- Single dose on Day 1

    Treatment: Influenza ModRNA Vaccine

  • SSC: QIV2Existing treatment, for comparison

    \- Single Dose on Day 1

    Treatment: Quadrivalent Influenza Vaccine (QIV)

  • SSC: QIV3Existing treatment, for comparison

    \- Single Dose on Day 1

    Treatment: Quadrivalent Influenza Vaccine (QIV)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS
Record updated
12 June 2026